Role of sirtuin 2 (SIRT2) in the drug resistance of melanomas.
2015/17/B/NZ5/00142
Keywords
Descriptors
- NZ5_1: Etiologia chorób człowieka
- NZ2_2: Genomika, transkryptomika i epigenomika
- NZ3_7: Przekaźnictwo sygnału
Panel
NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution
Instytut Biologii Medycznej PAN
Voivodeship: łódzkie
Principal investigator (from the host institution)
Number of co-investigators in the project: 4
Call
OPUS 9 – announced on 2015-03-16
- Amount awarded
- 577 200 PLN
- Project start date
- 2016-02-25
- Project end date
- 2019-10-24
- Project duration
- 44 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (2)
-
Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism.
- Authors:
- Karwaciak I, Sałkowska A, Karaś K, Dastych J, Ratajewski M.
- Academic press:
- International Journal of Molecular Sciences (year: 2021, volume: 22(9), pages: 5034), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/ijms22095034 – link to the publication
-
SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib.
- Authors:
- Karwaciak I, Sałkowska A, Karaś K, Sobalska-Kwapis M, Walczak-Drzewiecka A, Pułaski Ł, Strapagiel D, Dastych J, Ratajewski M.
- Academic press:
- Cancers (Basel) (year: 2019, volume: 11(5), pages: pii: E673), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/cancers11050673 – link to the publication